Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
6.29
+0.13 (2.11%)
Oct 27, 2026, 12:37 PM EDT - Market open
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or 74.37% compared to the previous year. That makes Agenus the 32,611th largest employer in the world and 4,247th in the United States.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,638,185
Profits / Employee
$1,133,272
Market Cap
283.18M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 111 |
| Alector | 103 |
| Scribe Therapeutics | 82 |
| Century Therapeutics | 78 |
| Vicore Pharma Holding AB | 46 |
| Inhibikase Therapeutics | 35 |
| Opus Genetics | 28 |
| Benitec Biopharma | 24 |
AGEN News
- 1 day ago - Agenus announces Phase 2 results from cohort of NEOASIS - TheFly
- 2 days ago - Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 - Business Wire
- 4 days ago - Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Business Wire
- 7 days ago - Agenus Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 17 days ago - Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference - Business Wire
- 19 days ago - Agenus announces Armenia granted marketing authorizations for BOT+BAL - TheFly
- 19 days ago - Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Business Wire
- 22 days ago - Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial - TheFly